Details for New Drug Application (NDA): 220103
✉ Email this page to a colleague
The generic ingredient in DAPSONE is dapsone. There are eight drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the dapsone profile page.
Summary for 220103
| Tradename: | DAPSONE |
| Applicant: | Zydus Lifesciences |
| Ingredient: | dapsone |
| Patents: | 0 |
Suppliers and Packaging for NDA: 220103
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| DAPSONE | dapsone | TABLET;ORAL | 220103 | ANDA | Zydus Lifesciences Limited | 70771-1979 | 70771-1979-1 | 100 TABLET in 1 BOTTLE (70771-1979-1) |
| DAPSONE | dapsone | TABLET;ORAL | 220103 | ANDA | Zydus Lifesciences Limited | 70771-1979 | 70771-1979-3 | 30 TABLET in 1 BOTTLE (70771-1979-3) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 25MG | ||||
| Approval Date: | Feb 26, 2026 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 100MG | ||||
| Approval Date: | Feb 26, 2026 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
